SCHEMBL4898281

SCHEMBL4898281

O=C(c1ccc(Cl)cc1)c1ccc2[nH]c(=O)nc(-c3cccc(Cl)c3)c2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.62
HSD17B10 Q99714 2/20 0.62
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
CASP1 P29466 1/20 0.62
NPSR1 Q6W5P4 1/20 0.62
PDE4A P27815 1/20 0.43
PDE4C Q08493 1/20 0.43
PDE4D Q08499 1/20 0.43
ALDH1A1 P00352 1/20 0.43
HPGD P15428 1/20 0.43
TSHR P16473 1/20 0.43
CSNK2A2 P19784 1/20 0.43
CSNK2B P67870 1/20 0.43
TDO2 P48775 1/20 0.41
RORB Q92753 2/20 0.41
PDE3B Q13370 1/20 0.39
PDE3A Q14432 1/20 0.39
ERBB2 P04626 1/20 0.39
PTK6 Q13882 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5654518 0.92 KDM4E (0.55) KDM4EHSD17B10MEN1KMT2ACASP1
SCHEMBL3552671 0.92 KDM4E (0.55) KDM4EHSD17B10MEN1KMT2ACASP1
SCHEMBL3559250 0.92 KDM4E (0.55) KDM4EHSD17B10MEN1KMT2ACASP1
SCHEMBL3556688 0.89 MEN1 (0.52) KDM4EHSD17B10MEN1KMT2ACASP1
SCHEMBL5550324 0.86 KDM4E (0.51) KDM4EHSD17B10MEN1KMT2ACASP1
SCHEMBL5658015 0.85 NPSR1 (0.50) KDM4EHSD17B10MEN1KMT2ACASP1
SCHEMBL5023770 0.85 KDM4E (0.52) KDM4EHSD17B10MEN1KMT2ACASP1
SCHEMBL1538310 0.80 MEN1 (0.59) KDM4EMEN1KMT2AHPGDMAPK1
SCHEMBL5026927 0.79 MEN1 (0.65) KDM4EHSD17B10MEN1KMT2ACASP1
SCHEMBL14039064 0.77 CSNK2A2 (0.47) KDM4EKMT2APDE4APDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8329714-B2 Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer JANSSEN PHARMACEUTICA NV (BE) 2012-12-11 US disclosed
US-8318753-B2 (-)-5-(3-Chlorophenyl)- alpha -(4-chlorophenyl)- alpha -(1-methyl-1H-imidazol-5-yl)tetrazolo-[1,5-a]quinazoline-7-methanamine and its pharmaceutically acceptable acid addition salts; anticancer agent JANSSEN PHARMACEUTICA NV (BE) 2012-11-27 US disclosed
US-20080114009-A1 Farnesyl Transferase Inhibiting 1,2-Annelated Quinoline Enantiomer VENET MARC GASTON 2008-05-15 US disclosed
US-20070259902-A1 FARNESYL TRANSFERASE INHIBITING 1,2-ANNELATED QUINOLINE ENANTIOMER VENEL MARC G 2007-11-08 US disclosed
EP-0977750-B1 FARNESYLTRANSFERASE INHIBITING QUINAZOLINONES JANSSEN PHARMACEUTICA NV (BE) 2007-07-04 EP disclosed
US-7173040-B2 Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2007-02-06 US disclosed
EP-1296984-B1 PHARMACEUTICAL COMPOSITION COMPRISING A FARNESYL TRANSFERASE INHIBITING 1,2-ANNELATED QUINOLINE ENANTIOMER JANSSEN PHARMACEUTICA NV (BE) 2005-05-04 EP disclosed
US-20040048882-A1 Farnesyl transferase inhibiting 6-(substituted phenyl) Methy)-quinoline and quinazoline derinazoline derivaties JANSSEN-CILAG S.A. (FR) 2004-03-11 US disclosed
EP-1322636-A1 FARNESYL TRANSFERASE INHIBITING 6- (SUBSTITUTED PHENYL)METHYL]-QUINOLINE AND QUINAZOLINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2003-07-02 EP disclosed
US-20030114471-A1 Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer JANSSEN PHARMACEUTICA N.V. (BE) 2003-06-19 US disclosed
EP-1296984-A1 FARNESYL TRANSFERASE INHIBITING 1,2-ANNELATED QUINOLINE ENANTIOMER JANSSEN PHARMACEUTICA N.V. (BE) 2003-04-02 EP disclosed
WO-2002024683-A1 FARNESYL TRANSFERASE INHIBITING 6-[(SUBSTITUTED PHENYL)METHYL]-QUINOLINE AND QUINAZOLINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2002-03-28 WO disclosed
US-6358961-B1 ADMINISTERING QUINAZOLINE DERIVATIVE FOR INHIBITING TUMOR GROWTH IN MAMMALS JANNSEN-CILAG S.A. (FR) 2002-03-19 US disclosed
WO-2001098302-A1 FARNESYL TRANSFERASE INHIBITING 1,2-ANNELATED QUINOLINE ENANTIOMER JANSSEN PHARMACEUTICA N.V. (BE) 2001-12-27 WO disclosed
US-6177432-B1 ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS JANSSEN-CILAG S.A. (FR) 2001-01-23 US disclosed
EP-0977750-A1 FARNESYLTRANSFERASE INHIBITING QUINAZOLINONES JANSSEN PHARMACEUTICA N.V. (BE) 2000-02-09 EP disclosed
WO-1998049157-A1 FARNESYLTRANSFERASE INHIBITING QUINAZOLINONES JANSSEN PHARMACEUTICA N.V. (BE) 1998-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040048882-A1 Farnesyl transferase inhibiting 6-(substituted phenyl) Methy)-quinoline and quinazoline derinazoline derivaties FNTB, FNTA, CYP7A1 KDM4E 1592/4885HSD17B10 639/4885MEN1 887/4885
US-20030114471-A1 Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer FNTB, FNTA, CYP7A1 KDM4E 3515/4885HSD17B10 346/4885MEN1 596/4885
US-20070259902-A1 FARNESYL TRANSFERASE INHIBITING 1,2-ANNELATED QUINOLINE ENANTIOMER FNTA, FNTB, CYP7A1 KDM4E 3278/4885HSD17B10 496/4885MEN1 593/4885
US-20080114009-A1 Farnesyl Transferase Inhibiting 1,2-Annelated Quinoline Enantiomer FNTA, FNTB, CYP7A1 KDM4E 3278/4885HSD17B10 496/4885MEN1 593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.